Related Experiment Video
Updated: Aug 27, 2025
Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform
Published on: April 12, 2021
The Ambulatory Medical Assistance (AMA) programme during active-phase treatment in patients with haematological
Anne-Sophie Michallet1, Stephanie Malartre1, Elodie Vignaud1
1Leon Berard Cancer Center, Lyon, France.
Context:
The need for patient navigator is growing, and there is a lack of cost evaluation, especially during survivorship.
Objective:
The objective of this study is to evaluate the cost-effectiveness of an Ambulatory Medical Assistance (AMA) programme in patients with haematological malignancies (HM).
Design:
A cost-effectiveness analysis of the AMA programme was performed compared to a simulated control arm.
Setting:
An interventional, single-arm and prospective study was conducted in a French reference haematology-oncology centre between 2016 and 2020.
Participants:
Adult patients were enrolled with histologically documented malignant haematology, during their active therapy phase, and treated either by intravenous chemotherapy or oral therapy.
Methods:
An extrapolation of the effectiveness was derived from a similar nurse monitoring programme (CAPRI study). Cost effectiveness of the programme was evaluated through adverse events of Grade 3 or 4 avoided in different populations.
Results:
Included patient (n = 797) from the AMA programme were followed during 125 days (IQR: 0-181), and adverse events (Grade 3/4) were observed in 10.1% of patients versus 13.4% in the simulated control arm. The overall cost of AE avoided was estimated to €81,113, leading to an ICER of €864.
Conclusion:
The AMA programme was shown to be cost-effective compared to a simulated control arm with no intervention.
